pneumococcal vaccine

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults at increased risk for pneumococcal disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX™23 when administered 6 months after receipt of either V114 or Prevnar 13™. Increased risk for pneumococcal disease is defined as 1) an underlying medical condition, 2) behavioral habits such as smoking, or 3) living in a community/environment with increased risk of disease transmission.

Therapeutic / Disease area: Vaccines

Condition: pneumococcal vaccine

Locations: Blacktown (NSW), Kippa Ring (QLD), Wyong (NSW)

Commencement date: 20/07/2018

Status: Recruitment active




Recommend this trial to your friend

For privacy purposes, please note that your friend's details will not be sent to us and will not be stored in our database. Please be assured that we will not contact them.







I have read the Privacy Policy.

Register interest in future trials











I have read the Privacy Policy.